Alterity Therapeutics (ATHE) Return on Capital Employed (2009 - 2024)

Alterity Therapeutics' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 189.03% for Q2 2024.

• On a quarterly basis, Return on Capital Employed rose 9432.0% year-over-year to 189.03% in Q2 2024; TTM through Jun 2024 was 189.03%, a 9432.0% increase from a year earlier, with the FY2023 full-year figure at 0.0%, up 4052.0% from the prior year.
• Return on Capital Employed rose to 189.03% in Q2 2024 per ATHE's latest filing, from 283.34% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 95.64% in Q2 2022 and bottomed at 283.34% in Q2 2023.
• The 3-year median for Return on Capital Employed is 189.03% (2024), against an average of 189.34%.
• Across the five-year window, Return on Capital Employed tumbled 18771 bps in 2023 and jumped 9432 bps in 2024, its largest moves.
• Year by year, Return on Capital Employed stood at 95.64% in 2022, then tumbled by 196 bps to 283.34% in 2023, then soared by 33 bps to 189.03% in 2024.
• Per Business Quant, the three latest ATHE Return on Capital Employed figures stand at 189.03% (Q2 2024), 283.34% (Q2 2023), and 95.64% (Q2 2022).